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Abstract: Biomarkers for predicting the risk of castration-resistant prostate cancer (CRPC) in men
treated with primary androgen deprivation therapy (ADT) are lacking. We investigated whether
Zinc-alpha 2 glycoprotein (AZGP1) expression in the diagnostic biopsies of men with hormone-naïve
prostate cancer (PCa) undergoing primary ADT was predictive of the development of CRPC and
PCa-specific mortality. The study included 191 patients who commenced ADT from 2000 to 2011.
The AZGP1 expression was evaluated using immunohistochemistry and scored as high or low
expression. The risks of CRPC and PCa-specific mortality were analyzed using stratified cumulative
incidences and a cause-specific COX regression analysis for competing risk assessment. The median
follow-up time was 9.8 (IQR: 6.1–12.7) years. In total, 94 and 97 patients presented with low and high
AZGP1 expression, respectively. A low AZGP1 expression was found to be associated with a shorter
time to CRPC when compared to patients with a high AZGP1 expression (HR: 1.5; 95% CI: 1.0–2.1;
p = 0.03). However, the multivariable analysis demonstrated no added benefit by adding the AZGP1
expression to prediction models for CRPC. No differences for PCa-specific mortality between the
AZGP1 groups were observed. In conclusion, a low AZGP1 expression was associated with a shorter
time to CRPC for PCa patients treated with first-line ADT but did not add any predictive information
besides well-established clinicopathological variables.
Keywords: prostate cancer; AZGP1; biomarker; androgen deprivation therapy
1. Introduction
Locally advanced and metastatic prostate cancer (PCa) at the time of diagnosis is associated with
a high risk of morbidity and mortality. Recent data suggest that de novo metastatic PCa accounts
for more than 60% of men eventually dying from the disease [1]. Androgen deprivation therapy
(ADT) remains the primary treatment for men with metastatic PCa. However, recent studies have
demonstrated that primary ADT combined with either chemotherapy or newer androgen receptor
targeting agents improves the survival in men with metastatic PCa [2–4].
Even though PCa initially responds to ADT, the majority of men managed on ADT will eventually
progress to castration-resistant prostate cancer (CRPC) [5,6]. For these men, the prognosis is grave,
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with a median estimated life expectancy of approximately two years [7]. The CRPC disease state is often
coupled with debilitating symptoms, such as pain from bone metastases, fatigue, and lower urinary
tract symptoms, which decrease the quality of life. Although several of the biological mechanisms
of CRPC have been described, there is wide variation in the time from commencing ADT to the
development of CRPC. Our lack of knowledge regarding tumor biology beyond the histopathological
pattern of growth included in the Gleason score (GS) may explain the current deficiency of the proper
prediction of PCa-related outcomes. Immunohistochemistry (IHC), the in situ hybridization of RNA or
DNA, and the genomic sequencing of different biomarkers on tissue biopsies are methods routinely
used to evaluate tumor biology and the malignant potential of cancers. Increasing our knowledge
of primary advanced hormone-naïve PCa by incorporating novel biomarkers could lead to better
predictive and prognostic models and thus provide a more personalized approach to treatment.
Zinc-alpha 2 glycoprotein (AZGP1) is an androgen-regulated biomarker in PCa with a potential
prognostic impact. A meta-analysis has demonstrated that low AZGP1 expression in tumor tissue
is an independent predictor of the time to biochemical failure following radical prostatectomy [8].
Furthermore, it was shown that AZGP1 is an independent predictor of time to CRPC and PCa-specific
mortality following radical prostatectomy [8–10]. Whether AZGP1 holds prognostic value at other
disease stages is, to the best of our knowledge, not known.
In the present study, we investigated the predictive value of AZGP1, which was assessed by
applying IHC to tumor tissue samples from men with locally advanced or metastatic PCa commencing
ADT as the primary treatment.
2. Materials and Methods
2.1. Patients and Follow-up Protocol
In the period January 1st 2000 to December 31st 2011, we identified 223 men diagnosed with locally
advanced or metastatic PCa, none of whom were considered candidates for curative therapy and all of
whom commenced ADT. The patients were followed throughout the period at the out-patient clinic,
department of Urology, Rigshospitalet, Denmark. A detailed description of the cohort and follow-up
have been presented previously [11]. In brief, the patients were treated with either continuous ADT
or the combination of castration with continuous anti-androgen treatment for maximal androgen
blockade. Clinical and pathological information was collected retrospectively from medical records
and included the age at diagnosis, the tumor, node, and metastasis (TNM) stage, prostate-specific
antigen (PSA) at the time of diagnosis, number of biopsies taken, GS on biopsies reevaluated according
to the International Society of Urological Pathology (ISUP) 2005 Gleason grading guidelines [12],
and primary treatment. Generally, the patients were followed in 3 months intervals with clinical
examination and PSA measurements. However, for cases with stable disease, 6 months intervals were
allowed for follow-up. The serum testosterone was measured in patients that showed increasing PSA.
The follow-up data included the time of progression to CRPC, the time and cause of death if applicable,
and any change in the PCa treatment. Prior, 32 patients were excluded due to incomplete follow-up
(n = 19), missing diagnostic specimens (n = 4), or insufficient tissue for further sectioning (n = 9).
Our study was conducted adhering to the Reporting recommendations for tumour marker
prognostic studies (REMARK) guidelines [13]. The study is approved by the Danish Data Protection
Agency (file#2007-58-0015; j.nr. 30-0882) and the Committees on Health Research Ethics in the Capital
Region of Denmark (H-2-2012-134).
2.2. Endpoints
The endpoints of the study were the risk of CRPC and PCa-specific mortality calculated from the
start of ADT. The progression to CRPC was defined in accordance with the European Association of
Urology guidelines as the castrate levels of testosterone in combination with biochemical progression
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or radiological progression [14]. In cases with missing data, CRPC was defined at the time when any
treatment approved for CRPC was started.
2.3. AZGP1 Immunohistochemistry
Immunohistochemical staining of the diagnostic specimen was performed using a 1:500 dilution of
anti-AZGP1 in accordance with a former protocol (HPA012582; Sigma Aldrich, St. Louis, MO, USA) [10].
The stained slides were digitalized using the Hamamatsu Nano ZoomerXR, and evaluation conducted
using the Hamamatsu NDP.view V.2.6.12 viewing software. The presence of intracellular AZGP1
immunoreactivity in biopsies was evaluated by one observer (M.D.W.). Each biopsy core was
given a score from 0 to 3 based on the fraction of positive tumor cells and the intensity of
cytoplasmic staining (Figure 1) [15] using a previously described and standardized approach [8,16].
The immunohistochemical assessment was performed blinded to all clinical endpoints.
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Figure 1. (A–D) Immunohistochemical Zinc-alpha 2 glycoprotein (AZGP1) staining in representative
prostate cancer biopsies displaying negative (A), weak (B), moderate (C), and strong (D) staining.
(E) 1 score table.
As each patient had multiple biopsi , ZGP1 score was calculated to r present the
combined im unoreactivity. The AZ s then dichotomized wit the pre-defined cutoff
points of ≤ 1.5 (low expression) and > expre sion) [15].
2.4. Statistics
The baseline clinical haracteristics were compared b twe n the AZGP1 groups with the Wilcoxon
rank-sum test for continuous variables and ×2 test for the categorical variables. The reverse
Kaplan–Meier method was used to calculate the median time to follow-up. Cumulative incidences of
the study endpoints were analyzed using the Aalen-Johansen method for competing risks, and Gray’s
test was used to assess differences between the AZGP1 groups. When analyzing for the risk of CRPC,
death before the event was treated as a competing event. Other cause mortality was considered a
competing event when analyzing the risk of PCa-specific mortality.
Univariable and multivariable models were performed for the risk of progression to CRPC and
PCa-specific mortality and included the AZGP1 expression (high vs low), age at treatment start,
log2-transformed PSA, clinical tumor stage, diagnostic GS, and a grouping of metastases. To assess the
discriminative bility of the multivariable models with and without the AZGP1 expression, receiver
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operating characteristic (ROC) curves and area under the curve (AUC) were used for the selected time
points. Statistical analyses were performed using R (R Development Core Team, Vienne, Austria).
All the tests were two-sided. p values < 0.05 were considered statistically significant.
3. Results
The final study cohort included 191 patients. The median number of biopsies available for the
AZGP1 IHC analysis was 4 (IQR: 3–6) per patient. Ninety-seven (51%) and 94 (49%) patients had high
and low AZGP1 expressions, respectively. The baseline characteristics are outlined in Table 1. Patients
with a low AZGP1 score had significantly higher clinical stages and worse pathological findings.
The median time from diagnosis to the start of ADT was 5 weeks (IQR: 3–12).
Table 1. Baseline characteristics.
Study Population
(n = 191)
High AZGP1
(n = 97)
Low AZGP1
(n = 94) p-Value
Age at treatment start, years,
median (range) 70.0 (52.4–89.7) 70.6 (52.4–89.7) 69.5 (52.5–89.1) 0.3
PSA at treatment start, µg/L,
median (IQR) 62.0 (30.0–202.5) 68.0 (30.0–187.0) 57.5 (30.0–228.0) 0.9
Clinical tumor category, n (%) 0.05
≤cT2 32 (16.8) 22 (22.7) 10 (10.6)
cT3a 61 (31.9) 34 (35.1) 27 (28.7)
cT3b 59 (30.9) 25 (25.8) 34 (36.2)
cT4 39 (20.4) 16 (16.5) 23 (24.5)
Diagnostic Gleason score, n (%) 0.002
≤7 38 (19.9) 28 (28.9) 10 (10.6)
8 59 (30.9) 31 (32.0) 28 (29.8)
9–10 94 (49.2) 38 (39.2) 56 (59.6)
Lymph node stage, n (%) 0.4
N0 1 (0.5) 0 (0.0) 1 (1.1)
N1 54 (28.3) 25 (25.8) 29 (30.9)
Nx 136 (71.2) 72 (74.2) 64 (68.1)
Metastasis at diagnosis, n (%) 0.1
M0 70 (36.6) 38 (39.2) 32 (34.0)
M1 114 (59.7) 53 (54.6) 61 (64.9)
Mx 7 (3.7) 6 (6.2) 1 (1.1)
Stage of disease *, n (%) 0.3
Locally advanced 40 (20.9) 22 (22.7) 18 (19.1)
Lymph node metastases only 37 (19.4) 22 (22.7) 15 (16.0)
Distant metastases 114 (59.7) 53 (54.6) 61 (64.9)
Primary ADT treatment, n (%) 0.2
LHRH treatment 176 (92.1) 89 (91.8) 87 (92.6)
Maximal androgen blockade 8 (4.2) 6 (6.2) 2 (2.1)
Orchiectomy 7 (3.7) 2 (2.1) 5 (5.3)
p-value: Wilcoxon rank-sum test for continuous variables and ×2 test for categorical variables. Abbreviations:
IQR: Interquartile range; LHRH: Luteinizing hormone-releasing hormone; TRUS: Transrectal ultrasound;
PSA: Prostate-specific antigen. * Locally advanced: N0/Nx and M0/Mx; Lymph node metastases only: N1 and
M0/Mx; Distant metastases: M1 and N0/Nx/N1.
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With a median follow-up of 9.8 (IQR: 6.1–12.7) years, a total of 125 (65%) patients progressed to
CRPC, 41 (21%) patients died of other causes before progressing to CRPC, and 25 (13%) did not progress.
The median time to CRPC was 2.9 (95% CI: 1.9–3.5) and 4.6 (95% CI: 3.2–6.1) years in men with low
and high AZGP1 expressions, respectively. A significant difference in the cumulative incidence of
developing CRPC between the AZGP1 low and high expression group was demonstrated (Gray’s test:
p = 0.03, Figure 2). A low AZGP1 expression was associated with a higher risk of developing CRPC
compared to a high expression in the univariable analysis (HR: 1.5; 95% CI: 1.04–2.1; p = 0.03).
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(B) prostate cancer (PCa)-specific death after the start of androgen deprivation therapy (ADT) treatment.
Com eting events are (A) death before the progression event and (B) death from other causes than PCa.
Patients were stratified based on the AZGP1 expression. p values for Gray’s test are reported.
In a multivariable cause-specific Cox regression analysis (Table 2), only higher PSA was associated
with a significantly higher risk of CRPC (HR: 1.2; 95% CI: 1.1–1.4; p < 0.0001). The discriminative ability
for the prediction of CRPC was not affected by including the AZGP1 expression in t e multivariable
model. The AUC for i cluding and omitt ng AZGP1 was 75.4 vs. 72.9 (p = 0 6) at 1 year and 70.0 vs.
66.3 after 5 years (p = 0.3) (Figure 3).
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Table 2. Uni- and multivariable cause-specific Cox proportional hazards of the risk of CRPC.
Univariable Analysis Multivariable Analysis
HR (95% CI) p Value HR (95% CI) p Value
AZGP1 expression
High REF REF
Low 1.5 (1.0–2.1) 0.03 1.3 (0.9–1.9) 0.2
Age at treatment start 1.0 (1.0–1.02) 0.5 1.0 (1.0–1.02) 0.6
PSA for 2-fold diff. 1.2 (1.1–1.4) <0.0001 1.2 (1.1–1.4) <0.0001
Clinical tumor category
≤cT2 REF REF
cT3a 1.2 (1.0–8.4) 0.5 0.9 (0.5–1.6) 0.7
cT3b 2.0 (0.6–6.4) 0.2 1.0 (0.5–1.7) 0.9
cT4 2.9 (0.9–9.6) 0.07 1.1 (0.5–2.0) 0.9
Diagnostic Gleason score
≤7 REF REF
8 1.4 (0.8–2.4) 0.2 1.1 (0.6–1.8) 0.9
9–10 1.8 (1.1–2.9) 0.02 1.5 (0.9–2.5) 0.1
Stage of disease *
Locally advanced REF REF
Lymph node metastases only 0.8 (0.7–1.8) 0.4 1.1 (0.6–2.0) 0.8
Distant metastases 1.2 (0.5–1.4) 0.5 1.0 (0.6–1.6) 1.0
Abbreviations: CI: Confidence interval; CRPC: Castration-resistant prostate cancer; HR: Hazard ratio;
PSA: Prostate-specific antigen. * Locally advanced: N0/Nx and M0/Mx; Lymph node metastases only: N1 and
M0/Mx; Distant metastases: M1 and N0/Nx/N1.
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3.2—not reached (NR)) and NR years (95% CI: 4.6-NR) for the AZGP1 low and high expression groups,
respectively. The 5-year cumulative incidence of PCa-specific mortality was 48% (95% CI: 40–57),
and the cumulative incidence of other cause mortality was 41% (95% CI: 32–50). No differences in
the risk of PCa-specific mortality was found when comparing the cumulative incidence for AZGP1
expression, although a trend was found (Gray’s test: p = 0.09; Figure 2). After adjustment for other
covariates, only PSA remained significantly associated with the risk of PCa-specific mortality (HR: 1.2;
95% CI: 1.1–1.4; p < 0.001) (Table 3). Adding the AZGP1 expression to the predictive model did not
increase the predictive ability of the model for predicting the PCa-specific mortality at 1 and 5 years
(Figure 4). Moreover, AZGP1 loss was not associated with CRPC or PCa-specific mortality when the
lowest AZGP1 intensity was used for each patient.
Table 3. Uni- and multivariable cause-specific Cox proportional hazards of the risk of
PCa-specific mortality.
Univariable Analysis Multivariable Analysis
HR (95% CI) p Value HR (95% CI) p Value
AZGP1 expression
High REF REF
Low 1.5 (1.0–2.4) 0.06 1.2 (0.7–1.9) 0.6
Age at treatment start 1.0 (1.0–1.0) 0.6 1.0 (1.0–1.0) 0.5
PSA for 2-fold diff. 1.2 (1.1–1.4) <0.0001 1.2 (1.1–1.4) 0.001
Clinical tumor category
≤cT2 REF REF
cT3a 1.6 (0.7–3.4) 0.3 1.1 (0.5–2.6) 0.8
cT3b 2.3 (1.1–5.0) 0.03 1.6 (0.7–3.5) 0.3
cT4 2.5 (1.1–5.6) 0.02 1.2 (0.5–3.0) 0.7
Diagnostic Gleason score
≤7 REF REF
8 1.5 (0.7–2.9) 0.3 0.9 (0.4–1.9) 0.8
9–10 2.0 (1.1–3.8) 0.0 1.5 (0.7–2.8) 0.3
Stage of disease *
Locally advanced REF REF
Lymph node metastases only 0.7 (0.3–1.6) 0.4 0.9 (0.4–2.1) 0.8
Distant metastases 1.5 (0.9–2.8) 0.2 1.3 (0.7–2.4) 0.5
Abbreviations: CI: Confidence interval; HR: Hazard ratio; PCa: Prostate cancer; PSA: Prostate-specific antigen.
* Locally advanced: N0/Nx and M0/Mx; Lymph node metastases only: N1 and M0/Mx; Distant metastases: M1 and
N0/Nx/N1.
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model for the risk of prostate cancer (PCa)-specific death with receiver-operating characteristic (ROC)
curves stratified by AZGP1 expression and omitting the AZGP1 status. Area under the ROC curve
(AUC) and p-values of the comparative tests are reported one ( ) and five (B) years after the start
of ADT.
4. Discussion
Our hypothesis was that a low AZGP1 expression could predict the early development of resistance
to hormone deprivation therapy in hormone-naïve PCa patients. AZGP1 is a secretory protein, and in
the prostate AZGP1 secretion is primarily regulated by androgen signaling. The increased expression
of AZGP1 mRNA has previously been demonstrated in the LNCaP cell line due to the binding of the
androgen receptor to androgen-responsive elements in the promoter region of the AZGP1 gene [17–19].
A low AZGP1 expression correlates with a worse pathological tumor stage and higher GS [16,20].
This has led to hypotheses that the loss of or low level of AZGP1 reflects the de-differentiation of the
epithelial programs in more aggressive PCa. This de-differentiation could precede the development of
disease progression to CRPC by bypassing the androgen receptor pathway [6,18]. Secondly, AZGP1
expression has been found to be associated with poor outcomes in several other cancers, including
hepatocellular carcinoma, gastric cancer, and breast cancer [21–23].
To the best of our knowledge, the present study is the first to analyze the predictive value of
AZGP1 expression in patients with locally advanced or metastatic PCa commencing ADT. We found
that patients with a low AZGP1 expression had a significantly higher rate of GS 9–10 and a higher
cT-category than patients with a high AZGP1 expression, which is in accordance with previously
published studies [8–10]. We found that the AZGP1 expression in tumor tissue is predictive of the
time to CRPC. However, after adjustment for other clinical and pathological variables, there was no
significant discriminatory improvement and no direct association between AZGP1 expression and
the development of CRPC. Neither did we find a significant association of AZGP1 expression with
the risk of PCa-specific mortality. Thus, the AZGP1 expression did not add any additional predictive
information for hormone-naïve PCa patients managed with ADT. There was no predictive value of
time to CRPC besides the level of PSA at diagnosis, which may relate to selection bias.
Several studies have demonstrated that a low AZGP1 expression is an independent predictor
of a shorter time to biochemical failure and initiating ADT, a shorter time to CRPC, and a greater
risk of PCa-specific mortality for men undergoing radical prostatectomy [8–10]. A meta-analysis
including 11,384 patients from eight different studies demonstrated that a low AZGP1 expression was
associated with biochemical failure with a HR of 1.7 following radical prostatectomy [8]. Furthermore,
previous research showed that adding AZGP1 expression levels resulted in a significant increase in
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the AUC from 78 to 83 and c-index from 0.618 to 0.662 in models predicting CRPC following radical
prostatectomy [8,10].
One explanation for the apparent lack of predictive information in the later phases of PCa could be
biological differences between localized PCa suitable for radical prostatectomy and advanced/metastatic
PCa. The recent studies by Kristensen et al. and Zhang et al. consisted of PCa patients undergoing
radical prostatectomy predominately for clinically localized disease (98% and 61%, respectively) and
with favorable GS (GS ≤ 7 (3 + 4) in 93% and 71%, respectively) [8,9]. In contrast, our population mainly
included locally advanced and high-grade GS, likely consistent with more aggressive phenotypes of
PCa. Poorly differentiated cancers may have multiple drivers of progression compared to lower-risk
tumors, and thus a single biomarker for addressing aggressiveness beyond GS seems overly simplistic.
These advanced tumors may have complex and heterogeneous biology and potential mutations in
several different pathways driving the disease, which seems too multifaceted for a single IHC marker
to be able to evaluate.
A recent study by Burdelski et al. applied certain subdivisions of tumors based on the IHC of
several biomarkers, namely AZGP1, ERG, and phosphatase and tensin-homolog (PTEN) [16]. In their
radical prostatectomy cohort, they found that a low AZGP1 expression correlated with ERG-positive
tumors and tumors with PTEN deletion and that these patients had an increased risk of biochemical
failure. The validation of these results in men with advanced PCa is still lacking, but such an approach
incorporating multiple biomarkers could provide better insight into the prognostics of AZGP1 in an
ADT cohort than looking at AZGP1 by itself as in this study.
Our study has limitations. Since the inclusion of patients into this study, the consensus of primary
treatment of metastatic hormone-naïve PCa has changed to include chemotherapy, enzalutamide,
or abiraterone acetate in first-line treatment for the selected patients, and thus the primary treatment
offered might not reflect the therapeutics used in a more up-to-date population. It is possible that the
AZGP1 expression would have performed better in a contemporary cohort. We do not expect that
the age of the biopsies could have affected the IHC assessment of AZGP1 expression. Studies have
shown a very slow degradation of antigens in paraffin embedding, with slight decay beginning after
15–20 years [24]. Sampling bias due to tumor heterogeneity and/or multiple tumors in the prostate
with varying phenotype has been and continues to be a hurdle in PCa research. Significant differences
in GS between biopsies and subsequent radical prostatectomy specimens have been established several
times [25,26]. With regards to AZGP1, Zhang et al. recently found no correlation between the AZGP1
expression in biopsies and RP specimens, and although the AZGP1 expression level in the RP specimens
was predictive for clinical endpoints, the biopsy AZGP1 expression was not [9]. This is somewhat in
agreement with our results and, although not possible to confirm, it is likely these technical aspects
interfere with the assessment of patients’ AZGP1 expressions. It is possible that the better sampling of
the prostate tumor by acquiring more biopsies for IHC analyses than the median of 4 in this study
would be necessary to better assess the AZGP1 expression of the hole PCa.
Biomarkers for predicting patients at risk of progression from hormone-naïve to CRPC remain an
unmet need in advanced PCa. Currently, androgen receptor variants such as AR-V7 have received
most attention, and also as tissue biomarkers. Qu et al. demonstrated that AR-V7 expression in men
with newly diagnosed PCa related to the time to CRPC in a multivariate analysis [27]. However, large
validation and prospective studies are needed to understand the value of AR variants at diagnosis.
A promising study on AR variants and other biomarkers in the treatment of mCRPC and soon de
novo metastatic PCa is ongoing [28]. We believe it is unlikely that any single biomarker will predict
progression, and we anticipate that panels of biomarkers (such as IHC or transcripts) will improve the
predictive performance. Additionally, recent advancements in technologies for analyzing circulating
tumor cells (CTC) could have a role by allowing the serial sampling of cancer-derived cells over
time. Several groups have reported sequencing analyses of CTCs that demonstrate the complex and
heterogeneous tumor biology of metastatic PCa in men treated with ADT and identify gene alterations
during the development of CRPC [29–31]. Other sequencing approaches, such as the analysis of
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cell-free DNA for mutations, structural alterations, and methylation, could also be used to understand
and predict the transition from the hormone-naïve to the resistant state [32,33]. As sequencing costs
continue to drop rapidly, there will be increasing opportunities to transition these technologies from
research tools to methods that can be applied in the clinic.
5. Conclusions
In this study of AZGP1 expression in PCa specimens from men with locally advanced or
metastatic disease managed with first-line ADT, we found that AZGP1 expression was predictive
of the development of CRPC. However, the AZGP1 expression did not add further predictive value
besides the known predictive clinicopathological features. Furthermore, AZGP1 was not found to be
predictive of PCa-specific mortality. Thus, in contrast with early-stage PCa, AZGP1 is unlikely to be a
valid biomarker in men commencing ADT.
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